Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ALLK Allakos Inc
- Stocks
- Healthcare
- NASDAQ: ALLK
Price (delayed)
$0.3285
Market cap
$29.69M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.79
Enterprise value
$5.47M
Allakos is a clinical stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Company's lead antibody, lirentelimab
Highlights
The company's quick ratio has surged by 198% QoQ
Allakos's debt has plunged by 100% YoY
The equity has declined by 47% year-on-year and by 30% since the previous quarter
Key stats
What are the main financial stats of ALLK
Market
Valuations
Earnings
Shares outstanding
90.38M
Market cap
$29.69M
Enterprise value
$5.47M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.53
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$75.87M
Net income
-$70.85M
EBIT
-$76.05M
EBITDA
-$60.3M
Free cash flow
-$88.69M
Per share
Balance sheet
Liquidity
EPS
-$0.79
EPS diluted
-$0.79
Free cash flow per share
-$0.99
Book value per share
$0.61
Revenue per share
$0
TBVPS
$0.66
Total assets
$59.55M
Total liabilities
$4.08M
Debt
$0
Equity
$55.46M
Working capital
$54.01M
Debt to equity
0
Current ratio
14.23
Quick ratio
13.54
Net debt/EBITDA
0.4
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-64.8%
Return on equity
-97.4%
Return on invested capital
-85.3%
Return on capital employed
-137.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ALLK stock price
How has the Allakos stock price performed over time
Intraday
0.18%
1 week
0.67%
1 month
3.14%
1 year
-74.53%
YTD
-72.85%
QTD
44.33%
Financial performance
How have Allakos's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$75.87M
Net income
-$70.85M
Gross margin
N/A
Net margin
N/A
The net income has soared by 67% YoY and by 39% from the previous quarter
The operating income has soared by 66% YoY and by 38% from the previous quarter
Price vs fundamentals
How does ALLK's price correlate with its fundamentals
Growth
What is Allakos's growth rate over time
Valuation
What is Allakos stock price valuation
P/E
N/A
P/B
0.53
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ALLK's EPS has surged by 68% year-on-year and by 39% since the previous quarter
ALLK's price to book (P/B) is 86% less than its 5-year quarterly average of 3.7 and 41% less than its last 4 quarters average of 0.9
The equity has declined by 47% year-on-year and by 30% since the previous quarter
Efficiency
How efficient is Allakos business performance
ALLK's return on equity is up by 29% since the previous quarter and by 15% year-on-year
The return on assets has grown by 23% year-on-year and by 22% since the previous quarter
The ROIC has grown by 23% YoY and by 20% from the previous quarter
Dividends
What is ALLK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ALLK.
Financial health
How did Allakos financials performed over time
The company's quick ratio has surged by 198% QoQ
The current ratio has soared by 196% QoQ
Allakos's debt is 100% less than its equity
Allakos's debt has plunged by 100% YoY
ALLK's debt to equity has plunged by 100% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.